

ISSN 2311-4673

Journal of Pharmacy and Pharmaceutical Sciences
(Volume 2, Issue 2, 2014)

The Management of Hypercholesterolemia with Herbal Medicine

Zeeshan Ahmad Sheikh¹, Khan Usmanghani^{1}*

¹Herbion Pakistan (Pvt.) Limited, Plot 30, Sector 28, Korangi Industrial Area, Karachi-74900, Pakistan

INTRODUCTION

It is the condition that is characterized by increased concentration of lipids or fats (triglycerides, cholesterol) and low density lipoproteins in the blood and decrease in high density lipoproteins. This increase of lipids in the blood can lead to serious heart diseases and pancreatitis. Most of the time hyperlipidemia has no symptoms and usually it has been diagnosed on routine lab investigation or during secondary investigations held primarily for other symptom or disease. Once baseline lipid levels are determined, they should be checked and controlled for every 3 to 4 months, or at least once a year. Regular aerobic exercise is shown to reduce

cholesterol. Discontinuing smoking and avoid or limit consumption of alcohol can also lower cholesterol. The plasma lipid levels recommended by National Cholesterol Education Program (NCEP), ATP (Adult Treatment Panel) III USA the desirable amount of "total Cholesterol" is less than 200 mg/dL, 200-239 mg/dL is borderline range, above or equal to 240 mg/dL is high range and for "triglycerides" normal value is less than 150 mg/dL, 159-199 mg/dL is borderline, 200-499 mg/dL is high, and equal or above than 500 mg/dL is very high. In case of "LDL-Cholesterol" the optimal value is less than 100 mg/dL, near optimal/ above optimal is from 100-129 mg/dL, borderline high is ranges 139-159 mg/dL, high value is 160-189 mg/dL, and very high, and equal or above 190 mg/dL. "HDL- Cholesterol" level

*Corresponding author: ugk_2005@yahoo.com

low is below 40 mg/dL, and high values is equal or above 60 mg/dL" ¹. Table 1 shows the detailed elaboration from NCEP ATP III USA Guidelines:

The depiction of healthy cholesterol levels and hypercholesterolemia are given in figure 1 and figure 2 where as in healthy cholesterol levels low density lipoproteins, triglycerides and high density lipoproteins have been figured out. In case of hypercholesterolemia low density lipoproteins, high lipoproteins are found in abundance that elicits the causes of hyperlipidemia.

Hypercholesterolemia

1. Mild hypercholesterolemia (borderline-high cholesterol): It is defined as the "total cholesterol in the range of 200 to 239 mg/dL". Epidemiological studies show that levels above 200 mg/dL twice increase risk for heart disease e.g. coronary heart diseases, therefore, the patients with cholesterol levels in the range 200 to 239 mg/dL should be clinically evaluated for risk factors.
2. Moderate hypercholesterolemia: "Plasma cholesterol with the range of 240 to 300 mg/dL and LDL-Cholesterol 160 to 210 mg/dL" is termed as moderate hypercholesterolemia. Normally, this is related to reduced activity of LDL receptors, defects of hepatic cholesterol metabolism, hypothyroidism and complications after menopause ².
3. Severe hypercholesterolemia (familial

Table 1

Recommended Healthy Levels Ages 2 – 18				
	Desirable	Borderline	High Risk	
Total Cholesterol	Less than 170	171-199	200 or more	
LDL Cholesterol	Less than 110	111-129	130 or more	
HDL Cholesterol	More than 60	36-59	35 or less	
Recommended Healthy Levels Ages 19 or older				
	Desirable	Acceptable	Borderline	High Risk
Total Cholesterol	Less than 180	181-199	200-239	240 or more
HDL Cholesterol				
Men	50 or more	45-49	35-44	35 or less
Women	60 or more	55-59	40-54	39 or less
Total Cholesterol / HDL Ratio				
Men	4.0 or less	4.1-5.0	5.1-6.5	6.6 or more
Women	3.3 or less	3.4-4.5	4.6-6.5	6.6 or more
LDL Cholesterol	100 or less	100-129	130-159	160 or more
Triglycerides	Less than 150	150-199	200-499	500 or more
Screening Recommendation				
Blood Cholesterol Levels	199 or less		200 or more	
Screening Frequency	Consult your physician for specific screening guidelines		A complete Cholesterol Panel is recommended. See your physician	
Source: American Heart Association and National Cholesterol Education Program Guidelines: 2008				

hypercholesterolemia):

It refers to the plasma concentration of cholesterol above 300 mg/dL and LDL over 210 mg/dL. It relates inherited defects in the gene encoding of the LDL receptors. Heterozygous familial hypercholesterolemia

is usually one in 500 people and manifests clinically with tendon xanthomas and premature coronary heart disease whereas homozygous forms are rare, i.e. one in 1,000,000. Hypothyroidism and nephritic syndrome may be the cause of severe hypercholesterolemia.




Figure.1 Healthy Cholesterol Levels




Figure.2 Hypercholesterolemia

In addition, many intervention studies have clearly demonstrated the role of low-density cholesterol (LDL-C) in mortality and morbidity due to heart diseases while high density cholesterol (HDL-C) is considered the good cholesterol helps in reverse cholesterol absorption^{3,4}.

Hypertriglyceridemia

It refers to increase plasma triglyceride levels over 250 mg/dL, generally in the range of 250 to 500 mg/dL. Endogenous hypertriglyceridemia also called type IV Hypercholesterolemia, which is characterized by increased VLDL, triglycerides. Diet-induces endogenous hypertriglyceridemia due to dietary factors like excessive caloric intake, excessive alcohol intake, stimulates the production of VLDL triglycerides. Primary endogenous hypertriglyceridemia is due to overproduction of VLDL triglycerides or defective lipolysis of VLDL, however, the reasons are poorly understood but insulin resistance could be one explanation. Among all causes the non-insulin dependent diabetes mellitus is common cause and requires good glycemic control to limit secondary hypertriglyceridemia. HMG-CoA is the only choice but their role is not fully established in hypertriglyceridemic diabetics.

Mixed Hypercholesterolemia

It refers to “increase plasma levels of the total cholesterol above than 240 mg/dL and above than 250 mg/dL triglycerides level”. Chylomicrons and VLDL are typically increased more than 500 mg/dL in marked hypertriglyceridemia with elevated cholesterol (type V hypercholesterolemia).

Clinical Manifestation

Initially it does not show any symptoms but most of the time it is diagnosed at screening. In its later stages, however, high cholesterol can cause

- Fatty deposits and skin tendon.
- Hepato-splenomegaly.
- Abdominal pain.

Epidemiological evidence

High risk of hypercholesterolemia is present worldwide however it is more so in India and Pakistan. According to a survey carried out in about 3143 adults >40 years of 12 randomly selected communities in Karachi, Pakistan, women were more likely to develop high cholesterol than men. The evidence shows that people living in South Asia have higher readings compared to the data equivalent of living in Europe, China and North America. This index can be used as a marker of the presence of small plates that may progress to rupture and contribute to coronary occlusion and ischemia potential⁵.

According to another study “conducted in the department of epidemiology and public health at University College London, UK”, the risk of developing cardiovascular disease in adult men belonging to the upper class, fed butter and saturated fats by sedentary with lipid profiles in the upper limits were higher compared to individuals belonging to low socioeconomic class with normal lipid profiles without hypertension in South Asia⁶.

Causes of Abnormal Lipid Profiles

Total and LDL Cholesterol: These may raise due to hereditary hypercholesterolemia (types IIa or IIb), taking diets that are high in saturated fats and cholesterol, under active thyroid, poorly controlled diabetes, liver disease, overactive pituitary gland, nephritic syndrome characterized by elevated cholesterol, loss of protein in the urine leading to low levels of protein in the blood and excessive fluid retention causing swelling, anorexia nervosa, certain medications.

These are raised due to variety of factors that includes genetic factors and age usually over age 45 in men and age 55 in women, menopause, lack of physical activity, certain medications e.g., diuretics, immunosuppressant, and corticosteroids. Chronic diseases like diabetes, hypothyroidism, cigarette,

high intake of dietary cholesterol, and obesity.

HDL cholesterol levels: There are some factors that may cause to lower down the level of beneficial cholesterol these includes malnutrition, cigarette smoking, certain medications (beta blockers and anabolic steroids), laziness, polycystic ovarian syndrome ⁷. HDL-Cholesterol particle have some basic functions to eliminate the products of LDL due to paraoxonase enzyme ⁸.

Reverse Cholesterol Transport: HDL-cholesterol are picked up by liver via SRB1 receptors (Scavenger receptor B, class 1) and ApoE receptors, also present in adrenal glands and ovaries, that selectively remove esterified cholesterol from liver. Hepatic cholesterol is then excreted in bile mediated by ABCG5/ ABCG8 transporters. Moreover, cholesterol linked to HDL is exchanged with Triglycerides of VLDL, IDL, and LDL resulting in TG enriched HDL-cholesterol.

Epidemiological studies on HDL-Cholesterol According to one study, “the HDL cholesterol is inversely related to both coronary heart disease and other cardiovascular disease mortality in both sexes”. According to study conducted by World Health Organization analyzed the data from 19 countries and showed “an inverse correlation between HDL-cholesterol and mortality due to coronary artery diseases”. Framingham study also showed an inverse correlation between HDL-Cholesterol and coronary artery diseases in male and female of different age groups, and also greater risk with HDL-Cholesterol as <40 mg/dl, regardless of LDL-Cholesterol values. Moreover, HDL-Cholesterol above 65 mg/dl provide protection against coronary events, even if LDL-Cholesterol 160 mg/dl.

In Lipid Research Clinics Prevalence Mortality Follow-up Study, it is shown that even 1 mg/dl increase in HDL-Cholesterol is associated with reduction of 3.5 % risk of coronary artery diseases, while HDL-cholesterol <35 mg/dl is associated with 3.7% mortality rate in men and 4.7% in women and the risk is 6 times higher for coronary artery diseases

⁹.

High triglycerides levels: Hereditary hypercholesterolemia (types I, IIb, III, IV, or V), diets high in calories, especially form sugar and refined carbohydrates, obesity, poorly controlled diabetes, insulin resistance, alcohol use, kidney failure, stress, pregnancy, polycystic ovarian syndrome, hepatitis, lupus, multiple myeloma, and lymphoma.

According to one study, high TG–low HDL-C, the characteristic dyslipidemia seen in insulin-resistant subjects, was at least as powerful predictor of IHD as isolated high LDL-C. The results suggest that efforts to prevent IHD should include intervention against high TG–low HDL-C, and not just against hypercholesterolemia ¹⁰.

Classification of triglycerides according to the National Cholesterol Education Program Adult Treatment Panel III is shown in table 2.

Table 2. Classification of triglycerides

1	Normal triglycerides < 150 mg/dL
2	Borderline-high triglycerides 150 - 199 mg/dL
3	High triglycerides 200 - 499 mg/dL
4	Very high triglycerides* = 500 mg/dL

Diagnosis

Diagnosis is done usually by testing lipid profile of the patients after an overnight fasting (10 to 12 hours). Adults with normal lipid profile should have their cholesterol checked after every five years and those who treated should cholesterol levels measured every two to six months and also liver functions tests.

The major risk factors that modify low-density lipoprotein include age, smoking status, hypertension, high-density lipoprotein levels, and family history. The concept of “CHD equivalent” is introduced— conditions requiring the same vigilance used in

patients with coronary heart disease. Patients with diabetes and those with a 10-year cardiac event risk of 20 percent or greater are considered CHD equivalents. Once low density lipoprotein cholesterol is at an acceptable level, physicians are advised to address the metabolic syndrome and hypertriglyceridemia.

Literature Search: Literature Search on herbal medicine has been extensively carried out however some of the representative herbs that are utilized are delineated herewith as follows. *Bombyx mori* Cocoon., *Commiphora mukul* Engl., *Trigonella foenum-graecum* Linn., *Origanum vulgare* Linn., *Rauwolfia serpentina* (L.) Benth. ex Kurz.

Commiphora mukul Engl.: The English and vernacular names of *Commiphora mukul* are Guggul, Salai tree. In Urdu it is termed as Muql, Gugal, Gugar while its botanical name is *Commiphora mukul* and belongs to family Burseraceae.



Figure.3 Leaves **Figure.4** (Gum) **Figure.5** Tree

Chemical Constituents: It contains Z-guggulsterone, E-guggulsterone, Z-guggulsterol, 16- α hydroxy-4-pregnen-3-one, 20 α -hydroxy-4-pregnen-3-one, 20 β -hydroxy-4-pregnen-3-one, guggulsterol -I, guggulsterol-II, guggulsterol-III, 3,5,6-cholestanetriol, 5-hydroxycholestane-3,6-dione, 16,20-dihydroxycholest-4,24-dien-3-one, mukulol, Cembrene-A, Myrcene, Myrcenol, D-xylouguggultetrol-18, 4,5 dihydro: 8,12 epoxy-1(10)4,7,11-germacratetaen-6-one and ferulic acid¹¹. The ketone fraction has the most potent cholesterol lowering components. These are composed of C21 or C27 steroids, with the major components being Z- and E-guggulsterone. It contains resin, volatile oil, and gum. Guggulsterones, the extract isolates ketonic steroid compounds and have the lipid-lowering

actions.

Pharmacological Properties: The compounds isolated from *Commiphora mukul* like cembrenoids, a bicyclic diterpene, guggulsterone derivatives, myrrhanonol derivatives, myrrhanol derivatives, and a lignan, inhibit the lipid peroxidation by 79, 57 and 58 % respectively¹². In a randomized, double blind study *Commiphora mukul* was proved to be hypolipidemic. It may decrease up to 11.7 % the total cholesterol level, 12.5 % the LDL-Cholesterol, 12.0 % triglycerides and 11.1 % the total cholesterol / HDL-Cholesterol ratio from the post diet levels compared with the placebo group¹³.

388 patients were enrolled with different diagnosis in six randomized clinical trials of *Commiphora mukul*, involving, five in India and one in the United States, 4 placebo-controlled and 1 compared guggul with 2 reference compounds reduced the total cholesterol from 10 % to 27 % and significant decrease in lipid peroxide levels¹⁴. According to another study, guggulsterone, inhibit the LDL oxidation that is mediated by either catalytic copper ions, free radicals that are generated with azo compound 2, 2-azobis-(2-amidinopropane) dihydrochloride (AAPH), or soybean lipoxygenase enzymatically, or the mouse peritoneal macrophages that reducing chances of atherogenesis¹⁵. In another study of twenty patients of Hypercholesterolemia, purified gum of *Commiphora mukul* in two divided doses of 4.5 gm daily for 16 days reduced serum cholesterol and triglyceride levels at the end of 4th and 8th weeks¹⁶.

Bombyx mori Cocoon: Common name of *Bombyx mori* is *Abresham*. It is an insect being a primary producer of silk. A silkworm's that preferred white mulberry leaves as food, but it may eat leaves of the other mulberry tree i.e. *Morus nigra* or *Morus rubra* as well as the Osage orange. For reproduction it is completely dependent on humans.

General Uses: It is promising as a reserve for solving a various biological problems¹⁷. In Unani medicine

it is also known as Abresham Muqirz¹⁸ and is also used in various formulations (Khameera-E- Abresham Sada, Khameera Abresham Hakeem Arshad Wala, Khameera Abresham Oud Saleeb Wala) and these are used for treating various ailments along with the Badranjboyaand Arjan^{19,20}. The crude extracts has protective role in hyperlipidemia and also have good antioxidant effect and beneficial effects for the management of hyperlipidemia²¹. Several formulations with large or small number of ingredients in Unani pharmacopoeia have been described for treating various ailments. But out of these some of the dosage forms in the Unani medicine have shown better results²². It is hot and dry in temperament. It is prescribed as nervine stimulant and also a cardiac tonic. It is an expectorant and can remove surplus 'Balghan' from the blood (Blagam – e – ghairtabae)²³. Recently it has been used to treat the, hypertension, heart diseases and palpitations²⁴.

Rauwolfia serpentina (L.) Benth. ex Kurz
Rauwolfia serpentina (L.) Benth. ex Kurz belongs to the family Apocynaceae and also cultivated in Karachi^{25,26}.



Figure 6. *Bombyx mori* Cocoon.

Chemical Constituents: Rauwolfia root contains almost 50 alkaloids that include reserpine, serpentina, deserpidine, ajmalicine, ajmaline, ajmalidine, sarpagine etc. Among all the principal alkaloid reserpine and rescinnamine in roots are majorly responsible for hypotensive activity^{27,28,29,30}. It was

also reported that the Rauwolfia contains not less than 0.15% of reserpine-rescinnamine group alkaloids, calculated as Reserpine^{31,32,33,34}. It was found in previous research study that it contains phytosterol, oleic acid, and unsaturated alcohols, five alkaloids, which were classified by them into



Figure 7. *Rauwolfia serpentina*

two groups; 1) The ajmaline group of three white crystalline, weak bases, ajmaline, ajmalinine, ajmalicine; and 2) the serpentine group of two yellow crystalline stronger bases, serpentine and serpentinine³⁵.

Pharmacological Properties: Recent research showed the major use of Rauwolfia roots is in the treatment of mild hypertension. Usually to prevent fluid retention it is given in combination with a diuretic herb that support its activity³⁶⁻⁴². It was also investigated that rauwolfia root powder is a potent hypolipidaemic agent especially having hypotriglyceridemic and hypo-cholesterolemic effects with undetectable side effects on liver and cardiac functions. Reserpine in Rauwolfia is powerful alkaloid has not shown any toxicity with same generic name of drugs. It has been used in the treatment of psychic and motor neuronal disorders, that including excitement, anxiety states, insanity insomnia and epilepsy from many centuries. It was reported that the powdered extract of root of Rauwolfia have efficacy to decrease the high blood pressure in experimental animals^{43,44}. Medicinally it is an important herb that has widespread spectrum of

therapeutic actions with majorly effective in the treatment of hypertension and psychotic disorders^{45,46}. It has unique properties of being slow onset of action but effect is sustained for longtime. By withdrawal of the prescribed medicine there may be chances of occurrence of cardiac and central nervous system effects. The metabolisms of active alkaloids




Figure 8. *Origanum vulgare* L.

into inactive compounds occur in liver that are excreted primarily in the urine⁴⁷.

Chemical Constituents: The plant contains 0.15-1.0% volatile oil in which chief components includes carvacrol (40-70%), p-cymene (5-10%), gamma-terpinene (8-10%), additionally alpha-pinene, thymol. Other components are flavonoids: including naringin, Caffeic acid derivatives: in particular, rosmarinic acid (5%)⁴⁸.

Pharmacological Properties: Leaves of Oregano are used as strong anti-hyperglycemic agents described in traditional practitioners⁴⁹. In one research study it was said that the extract of oregano have blood glucose lowering activity without effecting the basal plasma insulin concentrations in normal and streptozotocin (STZ) diabetic rats. The carvacrol principally in aromatic oregano water, is used in gastrointestinal disorders, also reduce blood cholesterol and glucose level and also used for tumor suppressive activities⁵⁰. In one animals study, the animals were treated with the infusion of oregano

showed lower blood glucose in comparison with the control group⁵¹. It is demonstrated in vitro studies that the ability to inhibit the aggregation and adhesion of blood platelets and cholesterol synthesis is due to oregano oil and its constituent substances, such as gamma-terpinene and carvacrol, whereas a decline was noticed in vivo study in the total cholesterol, triglycerides and both the systolic and diastolic readings in hypertension⁵².

Trigonella foenum graecum L.: *Trigonella foenum - graecum* (Linn.) belongs to the family Papilionaceae. It is an aromatic, 30-60 cm tall, annual herb, and cultivated throughout the country^{53,54}.



Figure 9. *Trigonella foenum-graecum*

Chemical Constituents: The major constituents of *T. foenum-graecum* are fibers, saponins, flavonoids, flavonoids, polysaccharides and polysaccharides fixed oils and some identified alkaloids i.e .trigonelline and choline^{55,56}. Seeds of Fenugreek also contains 45-60% carbohydrates, mainly mucilaginous fiber (galactomannans), 20-30% proteins high in lysine and tryptophan, 5 - 10% fixed oils (lipids), pyridine alkaloids, mainly trigonelline (0.2 - 0.38%), choline (0.5%), gentianine and carpaine, the flavonoids apigenin, quercetin, vitexin and isovitexin, free amino acids, such as 4-hydroxyisoleucine (0.09%), arginine, histidine and lysine, calcium and iron, saponins (0.6 - 1.7%), glycosides yielding steroidal sapogenins, vitamins A, B1, C and nicotinic acid, cholesterol and sitosterol,

and 0.015% volatile oils n-alkanes and sesquiterpenes^{57,58}. The seeds gave alkaloids, including trigonelline, carpaine; and saponins, based mainly on the saponin, diosgenin and its isomer yamogenin, gitogenin and tigogenin; flavonoids, including vitexin and its glycosides and esters and luteolin; a volatile oil in small quantities. *Pharmacological Properties:* It has been observed that flavonoids possess anti-oxidant activity^{59,60,61}. It was also reported that the seeds may raise the anti-oxidant levels. In number of clinical trials it was observed that the seeds have shown the efficacy as a hypoglycemic and anti-diabetic agent with minor or even no toxic manifestations^{62,63}. The results indicate that the extract of fenugreek seeds contains antioxidants and protects cellular structures from oxidative damage. These findings provide evidence for the in vivo beneficial effects of the seeds reported in the literature. The antiradical activity could be correlated with the polyphenolic components present in the extract. The results gained by these methods provide some important factors responsible for the antioxidant potential of fenugreek seeds and offer evidence for the large number of in vivo beneficial effects of the seeds reported in the literature⁶⁴.

Fenugreek was used for the treating various ailments i. e. wounds, joint pain, chest problems, and gastrointestinal affections. It was used by Traditional Chinese Herbalists for management of renal affections and male reproductive tract affections. It has been used as condiments for food preparation in various part of the world⁶⁵. The seeds are also used as tonic, expectorant, restorative, aphrodisiac, carminative, emmenagogue, and vermifugal properties. The seeds showed effects on serum cholesterol and glucose levels in condition from mild to moderate hypercholesterolemia or diabetes assessed by clinical studies in past.

CONCLUSION

From the above extensive literature search which was carried out with the assistance of a team comprises of professionals like botanist, herbalists,

Phytochemists and pharmacologists, it was concluded to add these botanicals in the formulation to produce a drug with the coded name "BIOCOR PLUS" Tablet for the treatment of hypercholesterolemia. The literature search showed enough evidences that supports the inclusion of the herbs and their extracts in the formulation to make it effective to normalize the blood cholesterol level especially considering total cholesterol and LDL-Cholesterol.

The herbs belong to Indo-Pak region, which makes their availability easier, these will be cost effective also and more importantly there were no major toxicity associated with these herbal raw materials and their good efficacy in hypercholesterolemia, makes them ideal candidates to be added into the formulation.

REFERENCES

1. Robert WM, Thomas PB. National Cholesterol Education Program Guidelines for Treatment: Managing Patients with Dyslipidemia. 10th edition, International edition, McGraw Hill New York, p 979 (2001).
2. Grundy SM., Disorders of Lipids and lipoproteins. *Annals of Internal Medicine.* (4) 1447-1452 (1994).
3. Young IS, McEneny J.. Lipoprotein oxidation and atherosclerosis. *Biochemical Society Transactions,* (29)2 (2001).
4. Cabezas MC, Van Heusden GP. Reverse cholesterol transport: relationship between free cholesterol uptake and HDL3 in normolipidaemic and hyperlipidemic subjects. *European Journal of Clinical Investigation,* (23)2, 122-129 (1993).
5. Jafar TH, Qadri Z. Global Burden of Cardiovascular disease, Coronary artery disease epidemic in Pakistan: more electrocardiographic evidence of ischemia in

- women than in men Heart, Pub Med Central, BMJ, UK., (94)408 (2008).
6. Whitty CJ, Brunner EJ, Shipley MJ, Hemingway H, Marmot MG. 1999. Differences in biological risk factors for cardiovascular disease between three ethnic groups in the Whitehall II study. *Atherosclerosis*. Feb;142(2):279-86 (1999).
 7. David R. Jacobs Jr., Irma L. Mebane, Shrikant I. Bangdiwala. High Density lipoprotein Cholesterol as Predictor of Cardiovascular disease mortality in men and women: The Follow-up study of the Lipid research clinics prevalence study. *American Journal of Epidemiology*., (131)1; 32-47 (1989).
 8. Forti N, Diament J. High-Density lipoproteins: Metabolic, Clinical, Epidemiological and Therapeutic Intervention Aspects. An Update for Clinicians, *Arquivos Brasileiros De Cardiologia*, (87)5; 614-616 (2006).
 9. Sirtori CR. HDL and the progression of atherosclerosis: new Insights. *European Heart Journal Supplements*; (8),4-9 (2003).
 10. Jeppesen J, Ole Hein H, Suadicani P, Gyntelberg F. Relation of High TG-Low HDL Cholesterol and LDL Cholesterol to the Incidence of Ischemic Heart Disease An 8-Year Follow-up in the Copenhagen Male Study, *Atherosclerosis, Thrombosis and vascular biology*, *American Heart Association* (17); 1114-1120 (1997).
 11. Francis J.A, Raja S.N, Nair M.G. Bioactive Terpenoids and Guggulosteroids from *Commiphora mukul* Gum Resin of Potential Anti-inflammatory Interest. *Chemistry and Biodiversity*, (1)11;1842 – 1853 (2004).
 12. Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of *Commiphora mukul* as an adjunct to dietary therapy in patients with hypercholesterolemia. *Cardiovascular Drugs and Therapy*,(8)4; 659- 664 (1994).
 13. Thompson Coon J.S, Ernst E. A systematic review Herbs for serum cholesterol reduction. *The Journal of Family Practice*, (52)6; 3-6 (2003).
 14. Wang X, Greilberger J, Ledinski G, Kager G, Paigen B, Jürgens G. The hypolipidemic natural product *Commiphora mukul* and its component guggulsterone inhibit oxidative modification of LDL. *Atherosclerosis*, 172; 239-246 (2004).
 15. Verma SK, Bordia A. Effect of *Commiphora mukul* (gum guggulu) in patients of hyperlipidemia with special reference to HDL-cholesterol. *Indian J Med Res*, 87:356- 360 (1988).
 16. Mondal M, Trivedy K, Kumar SN. The silk proteins, sericin and fibroin in silkworm, *Bombyx mori*Linn: A Review. *Caspian J Env Sci*;5:63-76 (2007)
 17. Kabeeruddin, Mughzanul, Mufarridath Lahore: Siddique Publications; pp. 30-60. (Text Book).
 18. Khan MB, Hoda MN, Yousuf S, Ishrat T, Ahmad M, Ahmad AS, Alavi SH, Haque N, Islam F. Prevention of Cognitive Impairments and Neurodegeneration By *Khamira Abresham Hakim Arshad Wala*. *J. Ethnopharmacol*; 108(1):68-73 (2006).
 19. TarikhNaseer Ahmed. *TajulMufarridath*. Jul;1 (Text Book) (2003).
 20. Kabeeruddin, Mughzanuk, Mufarridath Lahore: Siddique Publications; pp. 18-57.
 21. Tajuddin M, Ahmad NN. Effect of Unani formulation on lipid profile in rat. *Indian J*

- Pharmacol. 38:56–7 (2006).
22. Hakeem Ram Lubhaya. Vol. 2. Qasim Jan Street, Delhi: Shaktikumar Ayurvedic Acharya, Goswami Pharmacy; Goswami Bayanul Advia; p. 26 (1977).
 23. Mohammed Kamaluddeen Hussain Hamdani. Usool-E-Tib (Fundamentals of Tib) 45 (1980).
 24. Tarikh Naseer Ahmed. Tajul Mufarridath. Jul;1:30–1 (2003).
 25. Flora of Pakistan page number 25. http://www.efloras.org/florataxon.aspx?flora_id=5&taxon_id=200018451.
 26. WHO monographs volume I, page number 221
 27. Sarika R. Deshmukh, Dhanashree S. Ashrit and Bhausheb A. Patil. Extraction and Evaluation of Indole Alkaloids from Rauwolfia Serpentina for Their Antimicrobial and Antiproliferative Activities. International Journal of Pharmacy and Pharmaceutical Sciences, 4(5) (2012).
 28. Klyushnichenko, V.E., S.A. Yakimov, T.P. Tuzova, Ya V. Syagailo, I.N. Kuzovkina, A.N. Wulfson and A.I. Miroshnikov, Determination of indole alkaloids from R.serpentina and R.vomitoria by high performance liquid chromatography and high performance thin layer chromatography. J.Chromatography A, 704: 357-362 (1995).
 29. National formulary XIV. Washington, DC, National Formulary Board, American Pharmaceutical Association, (1975).
 30. Monachino J. Rauwolfia serpentina: Its history, botany and medical use. Economic botany, 8:349–365 (1954).
 31. Chopra, R.N.Gupta, J.C., and Mukherjee, B. The pharmacological action of an alkaloid obtained from Rauwolfia serpentina. A preliminary note, Ind., J.Med. Res., 21,261-71 (1933).
 32. Ray, G.K.Roy, P.K., Dasgupta S.R., et al, Action of Rauwolfia serpentina on vasomotor reflexes, Arch. Exp. Path. U. Pharmakol., 219,310-14 (1953).
 33. E.G. Mc Queen, A.E. Doyle, et al, “Mechanism of Hypotensive Action of Reserpine, an alkaloid of Rauwolfia serpentina”, Nature, 174, 1015 (1954).
 34. Tyler V.E., Brady L.R., Robbers J.E., Pharmacognosy, 9th edition, Lea and Febiger, Philadelphia, 222- 224 (1988).
 35. Rustom Jal Vakil. A CLINICAL TRIAL OF RAUWOLFIA SERPENTINA IN ESSENTIAL HYPERTENSION. From the Cardiological Department, King Edward Memorial Hospital, Bombay, India, January 4, 1949. http://repository.ias.ac.in/67930/1/18_PUB.pdf
 36. Physicians’ desk reference. 45th ed. Montvale, NJ, Medical Economics Company, (1991).
 37. Goodman and Gilman’s the pharmacological basis of therapeutics, 8th ed. New York, Pergamon Press, (1990).
 38. American Hospital Formulary Service drug information 94. Bethesda, MD, American Society of Health System Pharmacists, (1994).
 39. Bein HJ. The pharmacology of Rauwolfia. Pharmacology review, 8:435–483 (1956).
 40. Vakil RJ. A clinical trial of Rauwolfia serpentina in essential hypertension. British heart journal, 11:350–355 (1949).

41. Wilkins RW, Judson WE. The use of Rauwolfia serpentina in hypertensive patients. *New England journal of medicine*, 248:48–53 (1953).
42. Kline NS. Use of Rauwolfia serpentina Benth. in neuropsychiatric conditions. *Annals of the New York Academy of Science*, 59:107–132 (1954).
43. Hänsel R, Henkler G. Rauwolfia In: Hänsel R et al., eds. *Hagers Handbuch der Pharmazeutischen Praxis*, Vol. 6, 5th ed. Berlin, Springer-Verlag, 361-384 (1994).
44. Shamim A. Qureshi¹ and Shamsa K. Udani². Hypolipidaemic Activity of Rauwolfia serpentina Benth. *Pakistan Journal of Nutrition* 8 (7): 1103-1106, (2009)
45. S. A. Qureshi and S. K. Udani, “Hypolipidaemic activity of Rauwolfia serpentina Benth,” *Pakistan Journal of Nutrition*, vol.8, no. 7, pp. 1103–1106, (2009).
46. N. H. Mashour, G. I. Lin, and W. H. Frishman, “Herbal medicine for the treatment of cardiovascular disease: clinical considerations,” *Archives of Internal Medicine*, vol. 158, no. 20, pp. 2225–2234, (1998).
47. <http://restorativemedicine.org/pages/hypertension/#Anchor-43266>
48. <http://plants.usda.gov/java/ClassificationServlet?source=profile&symbol=ORVU&display=31>
49. http://www.efloras.org/object_page.aspx?object_id=96516&flora_id=5
50. Physician Desk Reference, 2000 page number 559
51. (Eddoukset al., 2002)
52. (Baser, 2002; Baser, 2008)
53. Daniel Pereira Coqueiro, Patricia Cincotto dos Santos Bueno, Elen Landragf Guiguer, Sandra Maria Barbalho, Maricelma da Silva Soares Souza, Adriano Cressoni Araújo, Cleber da Silveira Torres, Gustavo Scacco, Ana Maria Tiveron, Juliana Machado Costa, Layra Abib Vanzo, Leandro de Oliveira Silva, Murilo Salani Gil, Murilo Delboni Abib, Paulo Brito Reis Rossi, Rafael Fontes Ozi, Thays Delboni Abib, Ulisses Moraes Gonçalves Effects of oregano (*Origanum vulgare*) tea on the biochemical profile of Wistar rats. *Scientia Medica*, Vol 22, No 4 (2012).
54. http://www.naturafoundation.co.uk/monografie/Wild_oregano_oil.html
55. Kirtikar and Basu; “Indian Medicinal plants” International Book Distributors, 9/3, Rajpur Road (Ist floor) Dehradun-248001, India, Vol. I, Page. No.700-701.
56. “The Ayurvedic Pharmacopoeia of India”, Part-I, volume II, First edition, Govt. of India Ministry of health Education, Page No. 107-108.
57. Jayaweera D.M.A., Medicinal plant: Part III. Peradeniya, Sri Lanka: Royal Botanic Garden; Page No. 225 (1981).
58. Yoshikawa, M., Murakami, T., Komatsu, H., Murakami, N., Yamahara, J., Matsuda, H; Medicinal Foodstuffs: IV. Fenugreek seeds (1): structures of trigoneosides Ia, Ib, Iib, IIIa and IIIb new furostanolsaponins from the seeds of Indian *Trigonella foenum-graecum* L. *ChemPharmacol Bull*; 45: 81-7 (1997).
59. Budavari, S. The merck index: An encyclopedia of chemicals, drugs, and biologicals, 12th edn. Whitehouse Station, N.J. Merk & Co, Inc (1996).

60. Newall, C.A. Anderson, L. A. and Phillipson, J.D. Herbal medicines: A guide for healthcare professionals. The Pharmaceutical Press London (1996).
61. Mehrafarin, A. Qaderi, A. Rezazadeh, S. Badi, H. N. Noormohammadi, G. and Zand, E. Bioengineering of important secondary metabolites and metabolic pathways in Fenugreek (*Trigonella foenumgraecum* L.). *J. Medicinal Pl.* 9 (35): 1-18 (2010).
62. Moskaug, J.O., Carlsen, H., Myhrstad, M.C., Blomhoff, R. Polyphenols and glutathione synthesis regulation. *Am. J. Clin. Nutr.* 81, 277S–283S (2005).
63. Myhrstad, M.C., Carlsen, H., Nordstrom, O., Blomhoff, R., Moskaug, J.O. Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamyl-cysteine synthetase catalytic subunit promoter. *Free Radic. Biol. Med.* 32, 386–393 (2002).
64. Ozcan, A., Korkmaz, A., Oter, S., Coskun, O., Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats. *Arch. Toxicol.* 79, 461–465 (2005).
65. Gupta, A., Gupta, R., Lal, B. Effect of *T.foenum-graecum* (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. *J. Assoc. Phys. Ind.* 49, 1057–1061 (2001).